The open index of psychedelic research

Dose-dependent adverse events of esketamine in treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials.

Qu Y, Li S, Tian L +2

The esketamine-based multimodal low-opioid anaesthesia improves quality of recovery in elderly patients undergoing radical lung cancer surgery: a randomized controlled trial.

Zhou H, Wei J, Yang Z +7

Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: a case report.

Lago M, Cerveira M, Simonet JX

Drugs for anxiety: from chloral hydrate to novel therapeutics.

Haddad PM

The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.

Le GH, Wong S, Johnson DE +6

Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions.

LoParco CR, Rossheim ME, Tillett KK +7

Disproportionate carbon footprint of isoflurane in super-refractory status epilepticus

Anthost GdS, Preteux A, Tan D +3

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Mertens LJ, Betzler F, Brand M +24

Traces of the Other – Are DMT Entities Real? DMT Phenomenology in the Framework of Conscious Realism

Gallimore AR, Hermansson N, Hoffman DD

Correction: Catatonia Associated With First-Time Psilocybin Exposure: A Case Report.

Singh J, Mruthyunjaya P

Structural Neurotoxic and Neuroprotective Effects of Ketamine and Esketamine in Preclinical and Human Studies: A Systematic Review

Wasolua TT, Bommersbach TJ, McIntyre RS +1

Antidepressant effect of psychedelic compounds and mechanisms underlying the G protein-coupled receptors activation psychedelics: Antidepressant action and GPCR signaling.

Gollo Bertollo A, Alexandre Wippel V, Eduarda Dama Mingoti M +2

Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Bu F, Qin L, Lou Z +4

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs.

Glatfelter GC, Schalk SS, Walther D +9

Tending the Spiritual Workshops: Development, Evaluation, and Autoethnographic Assessment of Lessons Learned

Palitsky R, Peacock C, Gillis-Smith P +2

HaD-PET: Effects of DMT and harmine on cerebral glucose metabolism: FDG-PET dataset

Klemens Egger, Milan Scheidegger, Paul Cumming

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.

Urban MM, Zillich L, Rieser NM +5

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.

Giri Y, Furst P, Loo CK +2

Prophylactic interventions to prevent rebound pain after peripheral nerve block in adults: a systematic review and network meta-analysis of randomised controlled trials.

Singh NP, Makkar JK, Zhang C +2

Environmental and Internal Gating of Memory: ARCH Multiplicative Threshold Framework for Encoding and Retrieval

Rahman T

Persisting Psychological Complications Following the Use of Classic Psychedelics: A Qualitative Study of Help-Seeking Experiences

Jöbstl LM, Lubahn B, Kaya E +7

Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.

Berg CJ, LoParco CR, Rossheim ME +8

Can Childhood be Used as a Model to Understand the Effects of Psychedelics?

Hurwitz ES, Dean JG, Walker CM

Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review